These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 12745610)

  • 1. Therapeutic trials in ALS.
    Bradley W
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Apr; 4(1):6-7. PubMed ID: 12745610
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuroprotective agents for clinical trials in ALS: systematic assessment.
    Burke WJ
    Neurology; 2007 Feb; 68(9):709; author reply 710. PubMed ID: 17325287
    [No Abstract]   [Full Text] [Related]  

  • 3. Designing clinical trials in amyotrophic lateral sclerosis.
    Shefner JM
    Phys Med Rehabil Clin N Am; 2008 Aug; 19(3):495-508, ix. PubMed ID: 18625412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The advance in the research and therapeutic trials of amyotrophic lateral sclerosis].
    Moriwaka F; Tashiro K
    Rinsho Shinkeigaku; 2000 Dec; 40(12):1258-60. PubMed ID: 11464472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug therapy for amyotrophic lateral sclerosis: Where are we now?
    Carter GT; Krivickas LS; Weydt P; Weiss MD; Miller RG
    IDrugs; 2003 Feb; 6(2):147-53. PubMed ID: 12789618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is next in ALS clinical trials?
    Sorenson EJ
    Neurology; 2007 Aug; 69(8):719-20. PubMed ID: 17709702
    [No Abstract]   [Full Text] [Related]  

  • 7. A placebo arm is not always necessary in clinical trials of amyotrophic lateral sclerosis.
    Gordon PH
    Muscle Nerve; 2009 Jun; 39(6):858-60. PubMed ID: 19382169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotective agents for clinical trials in ALS: a systematic assessment.
    Traynor BJ; Bruijn L; Conwit R; Beal F; O'Neill G; Fagan SC; Cudkowicz ME
    Neurology; 2006 Jul; 67(1):20-7. PubMed ID: 16832072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALS lessons learned from other neurological diseases. Parkinson's disease.
    Fahn S
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():26-30. PubMed ID: 15512865
    [No Abstract]   [Full Text] [Related]  

  • 10. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selecting promising ALS therapies in clinical trials.
    Glass JD; Benatar M; Polak M
    Neurology; 2007 May; 68(18):1545-6; author reply 1546. PubMed ID: 17470765
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical development of levetiracetam for amyotrophic lateral sclerosis.
    Davies SL; Moral MA
    Drug News Perspect; 2006 Nov; 19(9):572-3. PubMed ID: 17220961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALS combination treatment. Drug cocktails.
    Rosenfeld J
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():115-7. PubMed ID: 15512890
    [No Abstract]   [Full Text] [Related]  

  • 14. [Riluzole treatment in amyotrophic lateral sclerosis].
    Wokke JH
    Ned Tijdschr Geneeskd; 1996 Nov; 140(46):2265-8. PubMed ID: 8984377
    [No Abstract]   [Full Text] [Related]  

  • 15. Selecting promising ALS therapies in clinical trials.
    Cheung YK; Gordon PH; Levin B
    Neurology; 2006 Nov; 67(10):1748-51. PubMed ID: 17130405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and experimental neuroprotection in neurodegenerative diseases is a therapeutic option for the future of amyotrophic lateral sclerosis (ALS). Preface.
    Ludolph AC; Drory VE
    J Neurol; 2000 Dec; 247 Suppl 6():VI/1. PubMed ID: 19714407
    [No Abstract]   [Full Text] [Related]  

  • 17. Any placebo controlled trial of riluzole would surely be unethical now.
    Ford M; Leperlier C
    BMJ; 2001 Sep; 323(7312):573-4. PubMed ID: 11573491
    [No Abstract]   [Full Text] [Related]  

  • 18. ALS trial design: expectation and reality.
    Miller RG; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():52-4. PubMed ID: 15512873
    [No Abstract]   [Full Text] [Related]  

  • 19. The biopharmaceutical industry and new drugs for amyotrophic lateral sclerosis.
    Malta E
    Adv Neurol; 1995; 68():263-9; discussion 271-5. PubMed ID: 8787239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measures of quality of life: con.
    Borasio GD
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2002; 3 Suppl 1():S21-3. PubMed ID: 12396797
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.